Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camonsertib and Olaparib in R/R CLL
NCT05405309Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of camonsertib in chronic lymphocytic leukemia (CLL), sponsored by University of Utah. Started Sep 2022; status: terminated.
02
Drugs
camonsertib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05405309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405309.